Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014255 · ClinicalTrials.gov registry record · Phase 2
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
- 5
- Study locations
NCT06014255 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 219 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06014255, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Conditions Studied
Interventions
- OTHER Standard of Care
- DRUG Enoblituzumab
Study Locations (5)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Illinois
- Northewestern University - Chicago
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Nebraska
- XCancer - Omaha, LLC - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06014255
The ClinicalTrials.gov registry entry for NCT06014255 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06014255 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Minnesota, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT06014255 about?
NCT06014255 is a clinical study titled "Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer". This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
What is the current status of trial NCT06014255?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2024-02-16. Estimated completion is 2029-03-01.
What conditions does trial NCT06014255 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06014255?
The interventions under investigation include: Standard of Care (OTHER), Enoblituzumab (DRUG).
Who is sponsoring clinical trial NCT06014255?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06014255 being conducted?
This trial has 5 study locations across Illinois, Maryland, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
-
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.